Project Grant K08AG098003
- The National Institute on Aging awarded Virginia Polytechnic Institute & State University $762,861 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on transcriptomic dynamics associated with TDP-43 propagation in limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC). The project will use quantitative neuropathology and high-resolution spatial transcriptomics to map the distribution of TDP-43, tau, and amyloid-beta...
- The National Institute on Aging awarded The Washington University $162,000 on March 1, 2026, under the Aging Research program (CFDA 93.866) to identify and characterize new therapy targets in TDP-43 proteinopathies. The award supports research into the mechanisms by which TDP-43 mislocalization results in neuronal death and aims to discover previously unidentified therapy targets that mediate this disease process. TDP-43 pathology is observed across multiple neurodegenerative diseases...
- The National Institute on Aging awarded the University of Pennsylvania $6.72 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to develop short RNA therapeutics targeting TDP-43 proteinopathy across amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, limbic-predominant age-related TDP-43 encephalopathy, and chronic traumatic encephalopathy. The recipient will identify and characterize short oligonucleotides that engage the TDP-43 protein,...
- The National Institute on Aging awarded the University of Utah $437,252 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate a plasma biomarker for TDP-43 proteinopathy in Alzheimer's disease and frontotemporal lobar degeneration. The project investigates MAB No. 9, a monoclonal antibody identified through screening over 5,000 antibody candidates that recognizes novel TDP-43 pathology in both diseases. Researchers will examine how MAB No. 9-positive TDP-43...
- The National Institute on Aging awarded the Regents of the University of Michigan $284,108 on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how mechanical changes in the aging brain affect microglial function and Alzheimer's disease progression. The project explores the relationship between age-related mechanical alterations in brain tissue—specifically decreased stiffness and increased viscoelasticity resulting from reduced tissue connectivity—and microglial...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded The Leland Stanford Junior University $682,281 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop a human induced pluripotent stem cell-based three-dimensional brain tissue microsphere model that recapitulates granulin deficiency phenotypes and associated pathology in neurodegenerative diseases including frontotemporal dementia and neuronal ceroid lipofuscinosis. The model...
- The National Institute on Aging awarded North Carolina Central University $673,720 on September 4, 2026, under the Aging Research program (CFDA 93.866) to develop fluid biomarkers for diagnosing limbic-predominant age-related TDP-43 encephalopathy (LATE) and differentiating LATE from Alzheimer's disease dementia. The project will develop TDP-43 seed amplification assay and tau-SAA as diagnostic tests for LATE, characterize the effects of co-existing TDP-43 pathology on tau pathology across...
- The National Institute on Aging awarded Pennsylvania State University, operating as Penn State Milton S. Hershey Medical Center, $479,579 under the Aging Research program (CFDA 93.866) on August 15, 2026, to investigate synaptic and metabolic alterations associated with TDP-43 proteinopathy in amyotrophic lateral sclerosis and frontotemporal dementia. The research identifies how mislocalization of TDP-43 protein from the nucleus to the cytoplasm disrupts synaptic vesicle cycling, RNA processing,...
- The National Institute on Aging awarded Regents of the University of Michigan $131,760 on August 1, 2026, under the Aging Research program (CFDA 93.866) to support research on hippocampal-prefrontal interactions underlying trace memory in aging and a rodent model of Alzheimer's disease. The investigator will perform simultaneous electrophysiological recordings in the hippocampus and calcium imaging recordings in the prefrontal cortex of freely moving rats as they perform a trace conditioning...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded the University of California, Los Angeles $146,750 under the Aging Research program (CFDA 93.866) on July 1, 2026, to identify molecular-neuropathological signatures in Alzheimer's disease, frontotemporal lobar degeneration, and long COVID. The recipient will employ single-cell spatial multi-omics on postmortem brain tissues to characterize molecular and cellular alterations linked to selective...
The National Institute on Aging awarded the Regents of the University of Michigan $126,969 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research determining the unique molecular and cellular features of limbic-predominant age-related TDP-43 encephalopathy (LATE). The recipient will compare the intrinsic properties of TDP-43 aggregates in FTLD-TDP (frontotemporal lobar degeneration with TDP-43 deposition) and LATE through high-resolution cryo-electron microscopy of post-mortem patient tissue, mass spectrometry analysis of post-translational modifications in patient samples (n=4), and HEK biosensor cell propagation assays. The work will employ spatial transcriptomics to map cell types and transcriptomic changes associated with TDP-43 pathology in both diseases, with the investigator developing skills in biochemical fractionation, cryo-EM workflow, spatial transcriptomics, and iPSC culturing and manipulation during the project period. Performance occurs at the University of Michigan in Ann Arbor, Michigan. The award extends from September 1, 2026, through June 30, 2031. This is a career development grant supporting a neuropathologist with clinical expertise in neurodegenerative disease diagnosis and staging alongside scientific expertise in TDP-43 biology.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $127.0k | 8/27/26 |